Variability in management and outcomes of therapy with eculizumab in atypical hemolytic uremic syndrome-Reference-Cited by-同舟云学术

Variability in management and outcomes of therapy with eculizumab in atypical hemolytic uremic syndrome

Published:2019-12-02 Issue:12 Volume:7 Page:525-533
ISSN:2167-8707
Container-title:Expert Opinion on Orphan Drugs
language:en
Short-container-title:Expert Opinion on Orphan Drugs

Author:

García-Martín Estela¹,Manrique-Rodríguez Silvia¹,Martínez Fernández-Llamazares Cecilia¹,Goicoechea-Diezhondino Marian²,Álvarez-Blanco Olalla³,García-Morín Marina⁴,Sanjurjo-Sáez María⁵

Affiliation:

1. Pharmacy Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain

2. Nephrology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain

3. Pediatric Nephrology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain

4. Pediatric Oncohematology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain

5. Director of Pharmacy Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Link

https://www.tandfonline.com/doi/pdf/10.1080/21678707.2019.1703108

Reference49 articles.

1. Syndromes of Thrombotic Microangiopathy

2. Syndromes of Thrombotic Microangiopathy

3. Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome

4. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference